Cargando…
OTHR-09. CENTRAL DIABETES INSIPIDUS: A RARE UNREPORTED SIDE EFFECT OF TEMOZOLOMIDE IN PEDIATRICS
Temozolomide is a chemotherapeutic agent commonly used in the treatment of central nervous system tumors. While there are case reports of temozolomide associated central diabetes insipidus (CDI) in adults, this has not been reported in children. We describe the first case of temozolomide associated...
Autores principales: | Kuo, Christopher, Waters, Kaaren, Cheung, Clement, Margol, Ashley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715846/ http://dx.doi.org/10.1093/neuonc/noaa222.634 |
Ejemplares similares
-
OTHR-09. The prevalence and complex management of MEK inhibitor induced cutaneous side effects
por: Meyer, Ashley, et al.
Publicado: (2022) -
OTHR-36. Management of Central Diabetes Insipidus (CDI) with Low-Dose Vasopressin Infusion in Patients with Non-Germinomatous Germ Cell Tumors (NGGCT) Requiring Hyperhydration during Chemotherapy
por: Fitzgerald, Caroline, et al.
Publicado: (2022) -
OTHR-17. Guidance for providing families with autopsy research results
por: Meyer, Ashley, et al.
Publicado: (2022) -
OTHR-16. Nutritional screening of U.S. pediatric central nervous system tumor survivors
por: Soja, Jacqueline, et al.
Publicado: (2022) -
OTHR-10. Pilocytic astrocytoma with respect to treatment
por: Hwee Tang, Phua, et al.
Publicado: (2022)